EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial

Liraglutid verbessert die periphere Perfusion und Marker der Angiogenese und Entzündung bei Menschen mit Typ-2-Diabetes und peripherer arterieller Verschlusskrankheit: 18-monatige Nachbeobachtung einer randomisierten klinischen Studie

Paola Caruso iD, Maria Ida Maiorino iD, Miriam Longo iD, Antonietta Maio, Lorenzo Scappaticcio iD, Nicole Di Martino, Carla Carbone, Mariluce Barrasso, Mariangela Caputo, Maurizio Gicchino, Giuseppe Bellastella iD, Dario Giugliano iD und 1 weitere

Diabetes, Obesity and Metabolism · 2025-07 · 27 (7) · 3891-3900

DOI: 10.1111/dom.16419 ↗

Auf einen Blick

Bei Menschen mit Typ-2-Diabetes und pAVK war Liraglutid nach 18 Monaten mit besserer peripherer Perfusion und günstigeren Entzündungs- und Angiogenesemarkern verbunden.

Fragestellung

Hält der in einer 6-monatigen Studie beobachtete Nutzen von Liraglutid bei Typ-2-Diabetes und pAVK über 18 Monate an?

Methode

STARDUST, randomisierte klinische Studie; Liraglutid bis 1,8 mg/Tag vs. maßgeschneiderte therapeutische Verordnungen zur kardiovaskulären Risikofaktorkontrolle bei 55 Teilnehmenden; Nachbeobachtung bis 18 Monate.

Ergebnisse

Nach 18 Monaten war TcPO2 unter Liraglutid höher als in der Kontrollgruppe: 10,9 mmHg (95 %-KI 7,6 bis 14,1; p < 0,001). Auch Albumin/Kreatinin-Ratio, CRP, Interleukin-6 und VEGF-A waren günstiger; progenitorische Zellmarker waren bei 6 und 18 Monaten höher.

Schlussfolgerung der Autor:innen

Bei Menschen mit Typ-2-Diabetes und pAVK erhöhte Liraglutid die periphere Perfusion und verbesserte über 18 Monate Marker der Angiogenese und Entzündung.

Kernaussagen

  • TcPO2 nach 18 Monaten unter Liraglutid höher: 10,9 mmHg (95 %-KI 7,6 bis 14,1)
  • Albumin/Kreatinin-Ratio, CRP und Interleukin-6 unter Liraglutid reduziert
  • Progenitorische Zellmarker und VEGF-A unter Liraglutid erhöht

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 25.04.2025. Verfasst von Paola Caruso und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolic Diseases, University of Campania "Luigi Vanvitelli", Naples, Italy. Hauptthemen laut MEDLINE: Liraglutide, Diabetes Mellitus, Type 2, Peripheral Arterial Disease, Inflammation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PhD program of Translational Medicine at the University of Campania "Luigi Vanvitelli", Naples, Italy (Dr. Caruso).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In a six‐month randomized clinical trial, improved peripheral perfusion has been shown with liraglutide, associated with favourable vascular effects in people with type 2 diabetes and peripheral artery disease (PAD). We aimed to evaluate the durability of these benefits and to elucidate some mechanisms underlying liraglutide's effect over an 18‐month follow‐up.

Methods

STARDUST was a randomized clinical trial which compared liraglutide up to 1.8 mg/day with tailored therapeutic prescriptions to manage cardiovascular risk factors in 55 participants with type 2 diabetes and PAD. We report data of people who have reached the 18‐month follow‐up for the primary outcome (transcutaneous oxygen pressure, TcPO 2 ) and also for additional secondary outcomes (markers of inflammation, angiogenesis and kidney function), as well as glycemic and metabolic parameters. TcPO 2 was assessed with transcutaneous oximetry. Circulating levels of angiogenic progenitor cells and serum inflammation markers were evaluated by flow cytometry and enzyme‐linked immunosorbent assay, respectively.

Results

Compared with the control group, significant differences favouring the liraglutide group were observed at 18 months for TcPO 2 [estimated treated difference (95% CI), 10.9 mmHg (7.6 to 14.1 mmHg), p < 0.001]. At 18 months of follow‐up, participants in the liraglutide group, as compared with those in the control group, had a significant reduction in urine albumin to creatinine ratio (estimated difference, −103.9 mg/g Cr, 95%CI, −170.8 to −37.1, p = 0.003), C‐reactive protein (−0.5 mg/dL, 95%CI, −0.8 to −0.2, p = 0.002), as well as interleukin‐6 (−32.6 pg/mL, 95%CI, −54.6 to −10.5, p = 0.004). Compared with the control group, participants in the liraglutide group showed significantly higher concentrations of circulating progenitor cells and endothelial progenitor cells at both 6 and 18 months, for CD34 + , CD133 + , KDR + , CD34 + /KDR + and CD34 + /CD133 + /KDR + . Liraglutide was also associated with a higher increase in vascular endothelial growth factor A at 18 months (70.1 pg/mL, 95%CI, 44.7 to 95.4, p < 0.001).

Conclusions

In people with type 2 diabetes and PAD, liraglutide increased peripheral perfusion, with amelioration of markers of angiogenesis and inflammation over an 18‐month follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideDiabetes Mellitus, Type 2Peripheral Arterial DiseaseInflammationHypoglycemic AgentsDiabetic AngiopathiesHumansMaleFemaleMiddle AgedFollow-Up StudiesAgedBiomarkersNeovascularization, PhysiologicAngiogenesis

Stichwörter der Autor:innen

angiogenesis markers circulating progenitor cells inflammatory markers Liraglut…peripheral artery disease randomized clinical trial type 2 diabetes

Substanzen

LiraglutideHypoglycemic AgentsBiomarkers

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolic Diseases, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • PhD Program of Translational Medicine, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

ORCID-Profile: Paola Caruso, Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Dario Giugliano, Katherine Esposito

Förderung

  • PhD program of Translational Medicine at the University of Campania "Luigi Vanvitelli", Naples, Italy (Dr. Caruso)

Zitieren

APA

Caruso, P., Maiorino, M. I., Longo, M., Maio, A., Scappaticcio, L., Di Martino, N., Carbone, C., Barrasso, M., Caputo, M., Gicchino, M., Bellastella, G., Giugliano, D., & Esposito, K. (2025). Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial. Diabetes, Obesity and Metabolism, 27(7), 3891-3900. https://doi.org/10.1111/dom.16419

Vancouver

Caruso P, Maiorino MI, Longo M, Maio A, Scappaticcio L, Di Martino N, et al. Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial. Diabetes, Obesity and Metabolism. 2025;27(7):3891-3900. doi:10.1111/dom.16419

BibTeX
@article{Caruso2025,
  author = {Caruso, Paola and Maiorino, Maria Ida and Longo, Miriam and Maio, Antonietta and Scappaticcio, Lorenzo and Di Martino, Nicole and Carbone, Carla and Barrasso, Mariluce and Caputo, Mariangela and Gicchino, Maurizio and Bellastella, Giuseppe and Giugliano, Dario and Esposito, Katherine},
  title = {Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {7},
  pages = {3891--3900},
  doi = {10.1111/dom.16419}
}
Kostenlos starten →